ATE226435T1 - Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwenung als pharmazeutischemetallchelatoren - Google Patents

Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwenung als pharmazeutischemetallchelatoren

Info

Publication number
ATE226435T1
ATE226435T1 AT97928269T AT97928269T ATE226435T1 AT E226435 T1 ATE226435 T1 AT E226435T1 AT 97928269 T AT97928269 T AT 97928269T AT 97928269 T AT97928269 T AT 97928269T AT E226435 T1 ATE226435 T1 AT E226435T1
Authority
AT
Austria
Prior art keywords
triazoles
diphenyl
substituted
metal chelators
pharmaceutical metal
Prior art date
Application number
AT97928269T
Other languages
German (de)
English (en)
Inventor
Rene Lattmann
Pierre Acklin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE226435(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE226435T1 publication Critical patent/ATE226435T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT97928269T 1996-06-25 1997-06-24 Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwenung als pharmazeutischemetallchelatoren ATE226435T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25
PCT/EP1997/003315 WO1997049395A1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Publications (1)

Publication Number Publication Date
ATE226435T1 true ATE226435T1 (de) 2002-11-15

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97928269T ATE226435T1 (de) 1996-06-25 1997-06-24 Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwenung als pharmazeutischemetallchelatoren

Country Status (36)

Country Link
US (3) US6465504B1 (h)
EP (1) EP0914118B1 (h)
JP (1) JP3541042B2 (h)
KR (1) KR100616378B1 (h)
CN (1) CN1146415C (h)
AP (1) AP1127A (h)
AR (1) AR007479A1 (h)
AT (1) ATE226435T1 (h)
AU (1) AU718037B2 (h)
BG (1) BG64248B1 (h)
BR (1) BR9709973A (h)
CA (1) CA2255951C (h)
CY (2) CY2429B1 (h)
CZ (1) CZ291470B6 (h)
DE (3) DE122007000020I1 (h)
DK (1) DK0914118T3 (h)
ES (1) ES2187785T3 (h)
FR (1) FR06C0049I2 (h)
GE (1) GEP20084355B (h)
HU (1) HU226232B1 (h)
IL (1) IL127212A0 (h)
LT (1) LTC0914118I2 (h)
LU (1) LU91291I2 (h)
MY (1) MY129541A (h)
NL (1) NL300248I2 (h)
NO (3) NO317180B1 (h)
NZ (1) NZ333308A (h)
OA (1) OA10946A (h)
PL (1) PL194758B1 (h)
PT (1) PT914118E (h)
RU (1) RU2208010C2 (h)
SI (1) SI0914118T1 (h)
SK (1) SK284319B6 (h)
TR (1) TR199802693T2 (h)
TW (1) TW533205B (h)
WO (1) WO1997049395A1 (h)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20090227647A1 (en) 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers
WO2005058320A1 (en) * 2003-12-19 2005-06-30 Novartis Ag COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
CN101203224B (zh) * 2005-01-28 2010-11-03 诺瓦提斯公司 嘧啶基氨基苯甲酰胺在制备治疗对Tie-2激酶活性的调节有响应的疾病的药物中的用途
BRPI0607058A2 (pt) * 2005-02-10 2009-08-04 Novartis Ag métodos para aumentar a disposição de fármaco
MX2007015085A (es) * 2005-05-31 2008-01-17 Novartis Ag Tratamiento de enfermedades del higado en donde el hierro juega un papel importante en patogenesis.
JP2009512652A (ja) * 2005-10-19 2009-03-26 ノバルティス アクチエンゲゼルシャフト 安息香酸誘導体含有分散錠
EP1945272B1 (en) * 2005-11-01 2013-09-11 Novartis AG Method of scintigraphy
ES2458615T3 (es) * 2006-02-03 2014-05-06 Taisho Pharmaceutical Co., Ltd. Derivado de triazol
KR20090007635A (ko) * 2006-05-09 2009-01-19 노파르티스 아게 철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
PT2026801E (pt) * 2006-05-23 2014-02-06 Novartis Ag Deferasorix para o tratamento da hemocromatose
TWI448285B (zh) 2006-07-13 2014-08-11 Los Angeles Biomed Res Inst 用以治療白黴菌症（ｍｕｃｏｒｍｙｃｏｓｉｓ）及其他真菌類疾病之組合物及方法
KR20090035737A (ko) * 2006-08-04 2009-04-10 노파르티스 아게 철 킬레이터를 이용한 내분비 기능장애의 치료
RU2339625C2 (ru) * 2006-11-02 2008-11-27 Российский химико-технологический университет (РХТУ им. Д.И. Менделеева) ЗАМЕЩЕННЫЕ N-[ω-АЗОЛ-1-ИЛ)АЛКИЛ]БЕНЗОЛСУЛЬФАМИДЫ В КАЧЕСТВЕ СРЕДСТВ С АНТИАГРЕГАЦИОННОЙ АКТИВНОСТЬЮ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
RU2468015C2 (ru) * 2006-11-29 2012-11-27 Новартис Аг Полиморфные формы деферасирокса (icl670a)
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
EP2108013A2 (en) * 2007-01-29 2009-10-14 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Crystalline forms of deferasirox
EP2144602A1 (en) * 2007-05-14 2010-01-20 Novartis Ag Use of iron chelator for the treatment of myocardial infarction
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
EP2062572A1 (en) 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
CZ301873B6 (cs) * 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
US20110097413A1 (en) * 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
US20110171138A1 (en) * 2008-06-02 2011-07-14 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
JPWO2010032489A1 (ja) 2008-09-22 2012-02-09 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
KR20110139743A (ko) 2009-03-19 2011-12-29 로스 엔젤레스 바이오메디칼 리서치 인스티튜트 엣 하버-유씨엘에이 메디칼 센터 모균증 및 다른 진균 질환의 치료를 위한 백신 조성물 및 방법
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
CN102638985A (zh) * 2009-12-07 2012-08-15 Mapi医药公司 地拉罗司的制备方法和地拉罗司多晶型物
CA2805568A1 (en) 2010-07-08 2012-01-12 Ratiopharm Gmbh Oral dosage form of deferasirox
EP2632907B1 (en) * 2010-08-25 2015-10-14 Davuluri, Ramamohan Rao Process for preparing 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparing deferasirox
BR112013007276A2 (pt) * 2010-10-01 2016-06-14 Cipla Ltd composição farmacêutica, processo para preparar uma composição farmacêutica, uso da coposição farmacêutica e método para tratar sobrecarga crônica de ferro
EP2643306B1 (en) 2010-11-24 2015-09-23 Alembic Pharmaceuticals Limited Process for the preparation of deferasirox
WO2012096183A1 (ja) 2011-01-14 2012-07-19 株式会社ダステック 高分子鉄キレート剤
US20140316534A1 (en) 2011-10-14 2014-10-23 Photocure Asa Stent
US20140276107A1 (en) 2011-10-14 2014-09-18 Photocure Asa Photodynamic diagnosis
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
KR102282372B1 (ko) * 2013-03-06 2021-07-27 바이오콘 리미티드 데페라시록스의 제조 방법
TWI686215B (zh) * 2013-03-08 2020-03-01 瑞士商諾華公司 祛鐵斯若(deferasirox)之口服配方
CN105377256A (zh) * 2013-05-10 2016-03-02 奇普拉股份有限公司 低剂量药物组合物
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
EP2946771B1 (en) 2014-05-20 2019-03-20 Sanovel Ilac Sanayi ve Ticaret A.S. Water-dispersible tablet formulation comprising deferasirox
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR102513870B1 (ko) 2014-10-14 2023-03-23 노파르티스 아게 Pd-l1에 대한 항체 분자 및 그의 용도
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
WO2017068089A2 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
US20190091204A1 (en) 2016-03-17 2019-03-28 Lupin Limited Compositions of deferasirox
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
US11155547B1 (en) * 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases
WO2022186809A1 (en) 2021-03-05 2022-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH84663A4 (h) 1963-01-24 1964-11-14
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
SU1280851A1 (ru) * 1983-07-08 1996-05-27 Ростовский государственный университет 1-фенил-3-алкил-5-(o-оксифенил)-1,2,4-триазолы, обладающие транквилизирующим и антигипоксическим действием, и 1-фенил-3-н-бутил-5-(о-оксифенил)-1,2,4-триазол, обладающий транквилизирующим, антигипоксическим и анальгетическим действием
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
DE122007000020I2 (de) 2010-12-30
SI0914118T1 (en) 2003-04-30
DK0914118T3 (da) 2003-02-24
CA2255951A1 (en) 1997-12-31
US6723742B2 (en) 2004-04-20
CN1223579A (zh) 1999-07-21
ES2187785T3 (es) 2003-06-16
OA10946A (en) 2003-02-27
SK178598A3 (en) 1999-06-11
KR100616378B1 (ko) 2006-08-28
CZ427298A3 (cs) 1999-03-17
IL127212A0 (en) 1999-09-22
JP2000507601A (ja) 2000-06-20
DE122007000020I1 (de) 2007-05-24
NL300248I2 (nl) 2007-03-01
WO1997049395A1 (en) 1997-12-31
AR007479A1 (es) 1999-10-27
NO2018014I1 (no) 2018-04-17
FR06C0049I2 (fr) 2007-04-27
PL330119A1 (en) 1999-04-26
BG64248B1 (bg) 2004-07-30
BR9709973A (pt) 1999-08-10
HK1020530A1 (en) 2000-05-12
GEP20084355B (h) 2008-04-29
LU91291I9 (h) 2018-12-27
AU3262997A (en) 1998-01-14
PT914118E (pt) 2003-02-28
NO986024L (no) 1998-12-21
CY2429B1 (en) 2004-11-12
NO2006017I2 (no) 2011-07-04
US20030203954A1 (en) 2003-10-30
TR199802693T2 (xx) 1999-05-21
NO986024D0 (no) 1998-12-21
JP3541042B2 (ja) 2004-07-07
HUP9903111A2 (hu) 2000-01-28
CZ291470B6 (cs) 2003-03-12
CA2255951C (en) 2006-10-10
RU2208010C2 (ru) 2003-07-10
NO2006017I1 (no) 2006-12-18
LTPA2007001I1 (lt) 2018-06-25
PL194758B1 (pl) 2007-07-31
EP0914118B1 (en) 2002-10-23
US6596750B2 (en) 2003-07-22
CY2007005I1 (el) 2010-07-28
MY129541A (en) 2007-04-30
BG103003A (en) 1999-09-30
AU718037B2 (en) 2000-04-06
DE69716602D1 (de) 2002-11-28
CY2007005I2 (el) 2018-12-12
HUP9903111A3 (en) 2000-06-28
HU226232B1 (en) 2008-07-28
NZ333308A (en) 2000-05-26
AP1127A (en) 2002-12-06
NO2018014I2 (no) 2018-11-19
CN1146415C (zh) 2004-04-21
AP9801407A0 (en) 1998-12-31
TW533205B (en) 2003-05-21
KR20050098029A (ko) 2005-10-10
NL300248I1 (nl) 2007-02-01
EP0914118A1 (en) 1999-05-12
FR06C0049I1 (h) 2007-03-09
US6465504B1 (en) 2002-10-15
LU91291I2 (fr) 2007-01-29
SK284319B6 (sk) 2005-01-03
US20030069273A1 (en) 2003-04-10
DE69716602T2 (de) 2003-06-26
NO317180B1 (no) 2004-09-06
LTC0914118I2 (lt) 2018-12-27

Similar Documents

Publication Publication Date Title
ATE226435T1 (de) Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwenung als pharmazeutischemetallchelatoren
DE69618959D1 (de) Pyrimidone und ihre verwendug als fungizide
DE69713284D1 (de) Triazol-Derivate als Arzneimittel
DE59710422D1 (de) Acylmercapto-triazolyl-derivate und ihre verwendung als mikrobizide
DE59200221D1 (de) Substituierte Triazole und ihre Verwendung als Herbizide.
DE59710423D1 (de) Triazolyl-mercaptide und ihre verwendung als mikrobizide
SK86699A3 (en) Nitrogen containing heteroaromatics as factor xa inhibitors
PT915846E (pt) Fenilcetoenois 2-substituidos e 2,5-substituidos
NL350023I1 (nl) Microbicide triazolylderivaten.
DE59710579D1 (de) Sulfonyl-mercapto-triazolyl-derivate und ihre verwendung als mikrobizide
DE69303864D1 (de) Neue 3,5-Diphenyl-substituierte 1,2,4-Triazole und ihre Verwendung als Insektizide und Akarizide
DE69629300D1 (de) Triazol enthaltende antifungale mittel
DE69613805D1 (de) Diiminoquinonderivate und ihre Verwendung als Elektronübertragungsmittel
DE69811018D1 (de) Triazol-Derivate und ihre Verwendung als antimykotische Mittel
FI931585A7 (fi) Uudet fungisidiset triatsoli- ja imidatsolijohdannaiset
DE59709790D1 (de) Mercapto-imidazolyl-derivate und ihre verwendung als mikrobizide
DE59711502D1 (de) Oximderivate und ihre verwendung als fungizide
PL335462A1 (en) Condensed azole derivatives, methods of obtaining them and their application as microbicides
DE59610382D1 (de) Halogenbenzimidazole und ihre verwendung als mikrobizide
DE59509781D1 (de) Alkylsulfinyl- und alkylsulfonyl-1,2,4-thiadiazolyloxyacetamide sowie ihre verwendung als herbizide
DE69607578D1 (de) Diiminoquinonderivate und ihre Verwendung als Elektronübertragungsmittel
DE69718850D1 (de) Heterocyclische N-Acetonylbenzamide und ihre Verwendung als Fungizide
ITPN940023A0 (it) Mobile metallico per comunita'
FI973845A7 (fi) Imidatsoli-, triatsoli- ja tetratsolijohdannaisia
KR960021778U (ko) 금속제 부품 보관구